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Abstract
Analyzing the effects on cell growth inhibition and/or cell death has been an important component of biological research.
The MTS assay and LDH-based cytotoxicity assays are two of the most commonly used methods for this purpose. However,
data here showed that MTS cell proliferation assay could not distinguish the effects of cell death or cell growth inhibition. In
addition, the original LDH-based cytotoxicity protocol grossly underestimated the proportion of dead cells in conditions
with growth inhibition. To overcome the limitation, we present here a simple modified LDH-based cytotoxicity protocol by
adding additional condition-specific controls. This modified protocol thus can provide more accurate measurement of
killing effects in addition to the measurement of overall effects, especially in conditions with growth inhibition. In summary,
we present here a simple, modified cytotoxicity assay, which can determine the overall effects, percentage of cell killing and
growth inhibition in one 96-well based assay. This is a viable option for primary screening for many laboratories, and could
be adapted for high throughput screening.
Citation: Smith SM, Wunder MB, Norris DA, Shellman YG (2011) A Simple Protocol for Using a LDH-Based Cytotoxicity Assay to Assess the Effects of Death and
Growth Inhibition at the Same Time. PLoS ONE 6(11): e26908. doi:10.1371/journal.pone.0026908
Editor: Klaus Roemer, University of Saarland Medical School, Germany
Received September 29, 2011; Accepted October 6, 2011; Published November 17, 2011
Copyright:  2011 Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by National Institute of Arthritis and Musculoskeletal and Skin (NIAMS) grant R01AR26427-18 to Dr. Norris and by a
Veterans Administration merit grant to Dr. Norris from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development. No additional external funding received for this study. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Yiqun.Shellman@UCDenver.edu (YGS); Shilo.Smith@UCDenver.edu (SMS)
. These authors contributed equally to this work.
Introduction
Analyzing the effects on cell growth inhibition and/or cell
death has been an important component of many biological
research, especially in cancer treatment development. Accurately
measuring the effects of treatments upon cells in vitro can be a
challenging task. Proliferation assays like MTT [1,2,3] and MTS
[4,5] as well as ATP based [6,7] assays are often used for primary
screening. The MTS assay relies on the metabolism of the MTS
reagent into formazan by dehydrogenase enzymes [4,5,8].
Proliferation assays like these have two major limitations: one
they can give false positive results where specific aspects of
cellular metabolism are affected [1], and two, they are unable to
differentiate cell cycle inhibition and cellular death [9,10]. To
overcome these, Promega suggests multiplexing the assay with an
LDH (lactate dehydrogenase) based cytotoxicity assay to allow for
further quantification without having to repeat the setup and
treatment phases. However, many therapeutic agents require
multiple replication cycles for a killing effect to be evident, and
dose dependent growth inhibition can act as a confounding
variable when using a LDH-based cytotoxicity assay with current
protocols, causing the amount of dead cells to be grossly
underestimated [3,9]. Here you will find a modified protocol
for an assay that will allow for the more accurate determination
of the total overall effect, the percentage growth inhibition as well
as the percentage of killing all in one 96 well format assay that
requires a simple absorbance plate reader and only one set of
assay reagents.
This protocol is for use with Roche’s cytotoxicity detection kit
(catalog number 11 644 793 001). It allows one to use this kit to
measure cellular death especially in experiments where relatively
long treatment times are needed or significant cell cycle inhibition
is present by adding condition specific controls. With this
modified protocol, one can determine the percentage of cell
death, overall effect as well as percentage of growth inhibition in
one assay.
Materials and Methods
Cell lines and culture conditions
A375 cells were obtained from ATCC (American Type Culture
Collection, Manassas, VA). Cells were maintained in RPMI 1640
medium (Sigma, St Louis MO) with 10% FBS (Gemini Bio-
Products, West Sacremento, CA) and grown with 5% CO2 in an
incubator at 37 degrees.
Cells were cultured in 96-well tissue culture plates at regular
culture conditions with appropriate cell number in 100 ml media
per well, and then being treated with bortezomib (LC laboratories,
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Houston, TX) for 72 hours before being subjected to indicated
assays.
Measurement of cell proliferation
The Cell Titer 96 Aqueous One solution cell proliferation assay
(MTS assay; Promega Corp., Madison, WI) was used to quantify
relative cell viability. Assays were performed according to the
manufacturer’s instructions.
Measurement of cell cytotoxicity with the standard
protocol
Cytotoxicity Detection Kit was purchased from Roche (India-
napolis, IN). TritonX-100 was purchased from Amersham
Biosciences (Piscataway, NJ). The standard protocol assays
reported here were performed according to the manufacturer’s
instructions.
Measurement of cell cytotoxicity with the modified
protocol
Two sets of replicates for each condition were used: one high
control and one for the actual assay. Replicates of 100 ml of media
without cells were used to serve as the blank for that condition.
After 24 hours the cells and blanks were treated with 100 mlo f
their respective drug solutions at predetermined concentrations in
serum free media.
On the day of the assay the cytotoxicty reagents were prepared
according to the manufacturer’s protocol. One non-sterile clean,
Figure 1. MTS cell proliferation assay could not distinguish the effects of cell death or cell growth inhibition. MTS assays were
performed on A375 cells that were treated with bortezomib (A) or PLX4720 (B). The Y-axis is the % of cells affected by the indicated treatment
compared to the total cells treated with vehicle control DMSO. The error bars are the estimated 95% confidence interval around the mean (see
Statistical analysis in Materials and Method section). C. Images of cells from the experiments performed for A and B. Results here are representative of
3 independent experiments.
doi:10.1371/journal.pone.0026908.g001
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assay plate for each experimental plate used. 4 ml (2% total
volume) of triton X-100 was added to each of the high control
wells, and mixed thoroughly using a multichannel pipette to
ensure the cells membranes were properly degraded. The plate
was then centrifuged for 5 min at 1000 RPM.
A multichannel was used to transfer 100 ml of supernatant
from the top of all the wells of the experimental culture plate to
the assay plate. Care was taken not to disturb the cells or draw
up any debris. 100 ml of the mixed detection kit reagent was
then added to each of the assay wells on top of the supernatant
in rapid succession. The total volume in each well was 200 ml.
The assay plates were then incubated at room temperature in
the dark for twenty minutes. After which they were read using
a standard plate reader with a reference wavelength of
490 nM.
Statistical analysis
To determine whether the difference in cytotoxicity estimates
for the two protocols was statistically significant, we boot-
strapped the data to estimate 95% confidence intervals around
the mean difference for each dosage level. We used a
bootstrapping approach because we only had three to four
trials at each dosage level, and thus could not reliably evaluate
the assumption of normality needed to use a z- or t- based
confidence interval (see R code in Supplemental materials, Text
S1). Briefly, we randomly selected from among all condition
assay wells, the media controls, and the condition-specific high
controls before computing the percent cytotoxicity by the new
protocol. This process was repeated 200 times for each protocol.
We then computed the differences between each of the
bootstrapped estimates for the modified and the standard
protocols (modified-standard). To compute the 95% confidence
interval, we sorted the estimates and excluded the lower and
upper 2.5%. Thus, the lower bound of the intervals was
computed by finding the 5
th lowest value and the upper limit by
finding the 95
th lowest value. The 95% confidence intervals
around the mean estimates for each protocol at each dosage
were computed in the same way, but using only the protocol-
specific estimates. That is, the 95% confidence intervals that
appear in the figures were computed by sorting the boot-
strapped estimates and excluding the upper and lower 2.5% of
values. For each dose level, if the 95% confidence interval
a r o u n dt h em e a nd i f f e r e n c eb e t w e e nt h ep r o t o c o le s t i m a t e sf o r
cytotoxicity did not include 0, then the difference in cytotoxicity
estimates was statistically significant at p#0.05. Likewise,
whenever the 95% confidence interval around the estimated
% cytotoxicity for one protocol does not contain the mean %
Figure 2. Original cytotoxicity protocol grossly underestimated the proportion of dead cells in conditions with growth inhibition.
A375 cells were treated with PLX4720 then assayed using standard protocol with Cytotoxicity Detection Kit (A). The Y-axis is the % of cells killed by
the indicated treatment compared to the total cells treated with vehicle control DMSO. The error bars are the estimated 95% confidence interval
around the mean (see Statistical analysis in Materials and Method section). (B) Images of cells from the experiments performed for A.
doi:10.1371/journal.pone.0026908.g002
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differences are statistically significant at p#0.05.
Results and Discussion
While there are a variety of assays available to determine the
effects of a specific condition, historically tetrazolium salt (XTT,
MTT, MTS) and ATP based assays have been used as a method
of performing preliminary screenings involving death and
proliferation studies[1,4,5,8,9,11,12,13]. It has long been known
that MTS and ATP based assays may overestimate the
effectiveness of a drug that alters cell metabolism but not cell
viability due to the fact that the assays measure cellular
metabolism as indirect readout for cell proliferation[1]. In
addition, our data also shows that these assays failed to
differentiate between cell death and growth inhibition (Figure 1).
The curves in Figure 1A and 1B have points representing
approximately 30% and 70% effectiveness on them as measured
by MTS assays. Additional morphological examination of these
conditions via light microscopy indicated that many of the cells in
20 nM bortezomib were dead, but the vast majority of the cells in
1.5 mM PLX4720 were alive (Figure 1C). Thus, the bortezomib
had killing effects on these cells while PLX4720 had cell-growth-
inhibition effects. However, the death and growth inhibition were
indistinguishable from the graphs in Figure 1A and 1B
demonstrating that MTS assays cannot distinguish the effects of
cell growth inhibition and cell killing. Similar results have been
observed in multiple cell lines and multiple treatments (data not
shown).
LDH and G6PD based assays can be used to determine the
percentage of dead cells under a given condition [3,9]. However,
in the presence of growth inhibition, such as we see with
PLX4720 treatment, the LDH based assay can grossly
underestimate the percentage of dead cells (Figure 2). This is
because the standard protocol bases the total possible LDH
release on a single control where Triton X-100 is added to the
culture to cause the breakdown of all of the cells. This is done on
the vehicle treated condition. The supernatant from these wells is
then used as a reference for the total possible amount of LDH.
LDH based assays are only able to detect cells that are in a late
enough stage of demise to release LDH. In cancer research, as in
other areas of research, there are many compounds that require
treatment times in excess of 48 hours to induce death. Herein
lies a problem with the original protocol; many of these
compounds also induce cell cycle arrest. Thus as time passes
the number of replication cycles in the control group becomes
increasingly higher than that of the treated groups, the total
number of cells and as a result the total LDH possible now varies
in a dose dependant manner.
Figure 2 illustrates this scenario: At 10 mM, a significant
percentage of the cells appear dead by morphological
examination, yet the cytotoxicity assay detects less than 10%
Figure 3. Comparison of experimental layout between the standard and modified protocols. Additional controls in the modified protocol
increased the accuracy as well as the amount of data obtainable from one assay. The added controls are shown in purple on a sample layout of the
modified protocol. The three equations used to analyze the data all utilize the added controls.
doi:10.1371/journal.pone.0026908.g003
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effects of PLX4720 (Figure 2B). Using the standard protocol,
t h et o t a lL D Hp o s s i b l ew a sb a sed on the controls for the
DMSO control, which had far more cells thus containing
higher amounts of total LDH than that in 10 mMt r e a t e d
conditions. To overcome this problem, one easy way is to
modify the standard protocol and use condition-specific-
controls for each condition by adding samples to be lysed by
Triton X-100 as the high control for each condition. This
would allow for more accurate calculation of the percentage of
cells killed in conditions even when significant cell growth
inhibition was present. Figure 3 illustrates the differences
between the modified protocol and the standard protocol.
As a result of using condition-specific-controls in the
calculations, the assay now indicates that 36% of these cells
are dead (Figure 4); a number that corresponds more closely with
what is visibly evident via light microscopy (Figure 2B). The
mean differences in estimated cytotoxicity and associated 95%
confidence intervals for each dose level are reported in Table 1.
Results indicated that there were dramatic differences in
estimates of cytotoxicity between the old and new methods,
statistical analysis also confirmed that significant differences
between these two methods, especially for the higher doses.
The total LDH controls can also be used to calculate the total
effect of a specific condition (Figure 3). If you were to subtract the
percent dead via the new method from the total affect you will
have the percentage of effective growth inhibition. Therefore, we
find that 46% of the effect in the 10 mM condition was growth
inhibition. Thus with one assay you can determine the percent of
inhibition, the percentage of cells killed and the total overall effect
of a drug or condition.
Table 2 compares the various commonly used, inexpensive,
primary screening methods that can be used for high
throughput screening. Our modified method is the only one
has the capacity to be quantitative, be able to distinguish cell
death versus growth inhibition without need of expensive
specialized equipment.
In summary, we present here a simple, modified cytotoxicity
assay that can determine the overall effects, percentage of cell
killing and growth inhibition in one 96-well based assay. While the
protocol is designed for a 96-well plate it could also easily be
modified to other plate styles for high throughput screening in
applications like drug discovery.
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Figure 4. Modified cytotoxicity protocol gave measurements of
overall effects on the cells and more accurate measurement of
percentage of dead cells in conditions with growth inhibition.
The experiment from Figure 2 was re-calculated using all of the controls
for the modified protocol. The total LDH from the control wells is also
plotted to show the overall effect of that condition. The same plot of
Figure 2 from old method is also presented here for comparison. The
error bars are the estimated 95% confidence interval around the mean
(see Statistical analysis in Materials and Method section). Whenever the
95% confidence interval around the estimated % cytotoxicity for one
protocol does not contain the mean % cytotoxicity for the other
protocol at the same dose level, the differences are statistically
significant at p#0.05.
doi:10.1371/journal.pone.0026908.g004
Table 1. Mean differences and 95% CI around the mean
difference in estimated % cytotoxicity for the two protocols
(modified protocol – standard protocol) at each dose level.
Dose (mM)
Mean
Difference (%)
Lower
Limit 95% CI
Upper Limit
95% CI
0.00 20.06 20.09 20.03
0.12 1.15 0.77 2.04
0.37 2.21 0.86 3.69
1.10 6.35 5.54 6.99
3.30 14.65 12.17 19.34
10.00 29.01 21.00 35.51
Note: For each dose level, if the 95% confidence interval around the mean
difference between the protocol estimates for cytotoxicity did not include 0,
then the difference in cytotoxicity estimates was statistically significant at
p#0.05.
doi:10.1371/journal.pone.0026908.t001
Table 2. Comparison of inexpensive, commonly used primary
screens.
Assay Quantitative
High
throughput
friendly)
Death VS
inhibition
Specialized
equipment
required
MTS, MTT, XTT Yes Yes No No
ATP based (glow) Yes Yes No No
Cytotoxicity if no growth
inhibition or
short time point
Yes No No
Modified
Cytotoxicity
Yes Yes Yes No
doi:10.1371/journal.pone.0026908.t002
LDH-Based Assay for Death and Growth Inhibition
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26908References
1. Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell
biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:
127–152.
2. Zeng FY, Cui J, Liu L, Chen T (2009) PAX3-FKHR sensitizes human alveolar
rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and
apoptosis. Cancer Lett 284: 157–164.
3. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: Comparison of LDH,
neutral red, MTT and protein assay in hepatoma cell lines following exposure to
cadmium chloride. Toxicology Letters 160: 171–177.
4. Buttke TM, McCubrey JA, Owen TC (1993) Use of an aqueous soluble
tetrazolium/formazan assay to measure viability and proliferation of lympho-
kine-dependent cell lines. J Immunol Methods 157: 233–240.
5. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble
tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun
3: 207–212.
6. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, et al. (2008)
Identification of a molecular signaling network that regulates a cellular necrotic
cell death pathway. Cell 135: 1311–1323.
7. Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, et al. (2010)
RNAi phenotype profiling of kinases identifies potential therapeutic targets in
Ewing’s sarcoma. Mol Cancer 9: 218.
8. Barltrop JA, Owen TC, Cory AH, Cory JG (1991) 5-(3-carboxymethoxyphenyl)-
2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and
related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) reducing to purple water-soluble formazans As cell-viability indicators.
Bioorganic & Medicinal Chemistry Letters 1: 611–614.
9. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, et al. (2009)
Guidelines for the use and interpretation of assays for monitoring cell death in
higher eukaryotes. Cell Death Differ 16: 1093–1107.
10. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, et al. (2009)
Classification of cell death: recommendations of the Nomenclature Committee
on Cell Death 2009. Cell Death Differ 16: 3–11.
11. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, et al. (1988)
Evaluation of a Soluble Tetrazolium/Formazan Assay for Cell Growth and
Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines. Cancer
Research 48: 4827–4833.
12. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, et al.
(1995) Early redistribution of plasma membrane phosphatidylserine is a general
feature of apoptosis regardless of the initiating stimulus: inhibition by
overexpression of Bcl-2 and Abl. J Exp Med 182: 1545–1556.
13. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G (2011) Cell death assays
for drug discovery. Nat Rev Drug Discov.2011/03/02 ed. pp 221–237.
LDH-Based Assay for Death and Growth Inhibition
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e26908